Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
pimavanserin
product2 mentionslast seen Sep 24, 2026
A selective serotonin inverse agonist sold under the brand name NUPLAZID.
Relationships 6
- Acadia Pharmaceuticals Inc.commercializespimavanserin99% confidence2 sources
- pimavanserinapplies toParkinson's disease psychosis98% confidence1 source
- United States Food and Drug Administrationapprovespimavanserin98% confidence1 source
- Acadia Pharmaceuticals Inc.developspimavanserin95% confidence1 source
- pimavanserinapplies toAlzheimer's disease psychosis90% confidence1 source
- pimavanserinapplies todementia-related psychosis85% confidence1 source
Relationship
Acadia Pharmaceuticals Inc.commercializespimavanserin
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 24, 2026ACADIA PHARMACEUTICALS INC 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis
- filingSEC EDGARSep 11, 2026ACADIA PHARMACEUTICALS INC 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company's lead commercial drug is pimavanserin, a selective serotonin inverse agonist sold under the brand name NUPLAZID®